Patheon N.V.
Healthcare · Pharmaceutical Preparations · P7 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY16 | FY15 | FY14 | |
|---|---|---|---|
| Revenue | $405.9M | $426.0M | $1.48B |
| Operating income | $197.7M | $181.6M | $13.4M |
| Net income | −$22.1M | −$6.2M | −$119.2M |
| Total assets | $2.64B | $2.62B | — |
| Total liabilities | $2.99B | $3.48B | — |
| Equity | −$348.4M | — | — |
| EPS (diluted) | — | — | — |
| Shares out. | 145.1M | 115.6M | 115.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2016- Operating margin
- 48.7%
- Net margin
- −5.4%
- Return on equity
- 6.3%
- Return on assets
- −0.8%
- Return on capital (ROCE)
- 9.6%
- Liabilities / assets
- 113.2%
- Debt / equity
- —
- Book value / share
- $-2.40
- Revenue growth (YoY)
- −4.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2016- Altman Z″ (distress)
- 0.38distress
- Accruals / assets
- −3.0%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 3 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Operating margin is positive
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Lagarde MichelOfficer — President | Aug 29, 2017 | U | 245,939 | — |
| Wilson Dean FrederickOfficer — Chief Accounting Officer | Aug 29, 2017 | U | 126,518 | — |
| Utiger LukasOfficer — President, Drug Substance Svcs | Aug 29, 2017 | U | 12,420 | — |
| Torres Raul CardonaOfficer — SVP, Quality | Aug 29, 2017 | U | 13,112 | — |
| Sherbet EricOfficer — General Counsel and Secretary | Aug 29, 2017 | U | 12,552 | — |
| Schneier Craig EricOfficer — EVP and Chief Talent Officer | Aug 29, 2017 | U | 48,755 | $35.00 |
| New Rebecca HollandOfficer — EVP, Enterprise Operations | Aug 29, 2017 | U | 10,306 | — |
| Negron Francisco R.Officer — President, Drug Product Svcs | Aug 29, 2017 | U | 11,231 | — |
| Mullen James COfficer — Chief Executive Officer | Aug 29, 2017 | U | 93,432 | — |
| Lehmann Michael J.Officer — EVP, Global Sales and Mktng | Aug 29, 2017 | U | 10,966 | — |
| Grant StuartOfficer — EVP and CFO | Aug 29, 2017 | J | 196,485 | — |
| Gill Harry R IiiOfficer — SVP, Quality/Continuous Imprvt | Aug 29, 2017 | U | 7,078 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer changeSep 5, 2017
- Delisting / listing-standard noticeAug 22, 2017
- Shareholder voteAug 2, 2017
- Other material eventJul 20, 2017
- Other material eventJul 17, 2017
- Results of operationsJun 8, 2017
- Entered a material agreementMay 19, 2017
- Other material eventMay 15, 2017
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BSep 13, 2017
- SC 13D/ASep 13, 2017
- SC 14D9/ASep 13, 2017
- SC TO-T/ASep 13, 2017
- SC 13DSep 7, 2017
- 8-KSep 5, 2017
- 25Sep 1, 2017
- 4FORM 4 SUBMISSIONAug 31, 2017
- 4FORM 4 SUBMISSIONAug 31, 2017
- 4FORM 4 SUBMISSIONAug 31, 2017
- 4FORM 4 SUBMISSIONAug 31, 2017
- 4FORM 4 SUBMISSIONAug 31, 2017
- 4FORM 4 SUBMISSIONAug 31, 2017
- 4FORM 4 SUBMISSIONAug 31, 2017
- 4FORM 4 SUBMISSIONAug 31, 2017
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.